Congratulations to Andrew Eustace who passed his PhD viva with minor corrections on April 24th 2017.
Andrew’s research, supervised by Dr Jim Middleton and Dr Angela Nobbs, focussed on syndecan-3 (a heparan sulfate proteoglycan) and inflammation.
A major function of the syndecan family is to present chemo-attractants to circulating white blood cells, helping direct them to sites of inflammation. Andrew’s thesis assessed how the endothelial expression of syndecan-3 varies in response to an inflammatory stimulus, the use of syndecan-3 as a biomarker in rheumatoid arthritis and also the potential of soluble syndecan-3 as a novel anti-inflammatory agent.
Andrew has been accepted for a post-doc at INSERM Paris, and departs Bristol on the 11th of May.
Congratulations Andrew!